1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Norway Pharmaceuticals and Healthcare Report Q2 2016

Norway Pharmaceuticals and Healthcare Report Q2 2016

  • April 2016
  • -
  • Business Monitor International
  • -
  • 65 pages

Includes 3 FREE quarterly updates
Table Of Contents

Norway Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals And Healthcare Forecasts (Norway 2014-2020) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Norway 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Norway 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2014-2020) 26
Industry Risk/Reward Index 27
Western Europe Risk/Reward Index 27
Norway Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Pricing Regime 36
Reimbursement Regime 37
Market Overview 40
Healthcare Sector 41
Table: Healthcare Resources (Norway 2010-2015) 42
Table: Healthcare Personnel (Norway 2010-2015) 43
Table: Healthcare Activity (Norway 2010-2015) 43
Research And Development 43
Clinical Trials 45
Epidemiology 46
Competitive Landscape 49
Table: The Top 25 Pharmaceutical Companies In Norway 50
Table: Multinational Market Activity 51
Demographic Forecast 54
Table: Population Headline Indicators (Norway 1990-2025) 55
Table: Key Population Ratios (Norway 1990-2025) 55
Table: Urban/Rural Population and Life Expectancy (Norway 1990-2025) 56
Table: Population By Age Group (Norway 1990-2025) 56
Table: Population By Age Group % (Norway 1990-2025) 57
Glossary 59
Methodology 61
Pharmaceutical Expenditure Forecast Model 61
Healthcare Expenditure Forecast Model 61
Notes On Methodology 62
Risk/Reward Index Methodology 63
Index Overview 64
Table: Pharmaceutical Risk/Reward Index Indicators 64
Indicator Weightings 65

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.